Ensysce Biosciences, Inc.
ENSC
$2.17
-$0.30-12.15%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -1.74% | 124.61% | 11.84% | -42.44% | 36.19% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -100.00% | -- | -- | -- | -- |
| Total Other Non-Cash Items | -92.45% | -58.71% | -22.85% | 120.53% | 214.13% |
| Change in Net Operating Assets | 270.96% | -545.07% | 56.99% | -29.67% | -73.02% |
| Cash from Operations | 57.59% | 54.91% | 25.69% | 5.50% | 45.32% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 33.36% | 30.34% | 91.25% | -3.05% | 88.85% |
| Issuance of Common Stock | -- | -- | -100.00% | -22.83% | -100.00% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | 100.00% | 2,292.16% | 100.00% |
| Cash from Financing | -92.29% | 4,129.95% | -100.93% | 203.42% | -24.69% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -91.17% | 231.51% | -197.82% | 231.69% | 74.86% |